Biomarkers for the efficacy of somatostatin analogue treatment

Details for Australian Patent Application No. 2004294269 (hide)

Owner Novartis AG

Inventors Saulnier, Muriel

Agent Davies Collison Cave

Pub. Number AU-A-2004294269

PCT Pub. Number WO2005/053732

Priority 60/525,079 25.11.03 US

Filing date 24 November 2004

Wipo publication date 16 June 2005

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

A61K 38/31 (2006.01) Medicinal preparations containing peptides - Somatostatins

Event Publications

1 June 2006 PCT application entered the National Phase

  PCT publication WO2005/053732 Priority application(s): WO2005/053732

6 November 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004294278-Reduced-fat flavored coating and methods of using same

2004294268-Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment